Abbott Laboratories Competitors

Medtronic (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional & Insider Ownership

79.5% of Medtronic shares are owned by institutional investors. Comparatively, 73.0% of Abbott Laboratories shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 1.5% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

Medtronic pays an annual dividend of $2.52 per share and has a dividend yield of 1.9%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Abbott Laboratories pays out 49.3% of its earnings in the form of a dividend. Medtronic has increased its dividend for 44 consecutive years and Abbott Laboratories has increased its dividend for 49 consecutive years.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Medtronic and Abbott Laboratories, as reported by MarketBeat.

Medtronic presently has a consensus target price of $135.1364, indicating a potential upside of 2.91%. Abbott Laboratories has a consensus target price of $124.6667, indicating a potential upside of 3.05%. Given Abbott Laboratories' higher probable upside, analysts plainly believe Abbott Laboratories is more favorable than Medtronic.

Profitability

This table compares Medtronic and Abbott Laboratories' net margins, return on equity and return on assets.

Volatility and Risk

Medtronic has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Valuation and Earnings

This table compares Medtronic and Abbott Laboratories' revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Medtronic.

Summary

Abbott Laboratories beats Medtronic on 9 of the 16 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional & Insider Ownership

83.7% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 73.0% of Abbott Laboratories shares are owned by institutional investors. 0.9% of Intuitive Surgical shares are owned by insiders. Comparatively, 1.5% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Intuitive Surgical and Abbott Laboratories, as reported by MarketBeat.

Intuitive Surgical presently has a consensus target price of $939.3529, indicating a potential downside of 5.26%. Abbott Laboratories has a consensus target price of $124.6667, indicating a potential upside of 3.05%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Abbott Laboratories is more favorable than Intuitive Surgical.

Profitability

This table compares Intuitive Surgical and Abbott Laboratories' net margins, return on equity and return on assets.

Volatility and Risk

Intuitive Surgical has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

Valuation and Earnings

This table compares Intuitive Surgical and Abbott Laboratories' revenue, earnings per share and valuation.

Abbott Laboratories has higher revenue and earnings than Intuitive Surgical. Abbott Laboratories is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Stryker (NYSE:SYK) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Stryker and Abbott Laboratories, as reported by MarketBeat.

Stryker presently has a consensus target price of $280.8696, indicating a potential upside of 3.66%. Abbott Laboratories has a consensus target price of $124.6667, indicating a potential upside of 3.05%. Given Stryker's higher probable upside, equities analysts plainly believe Stryker is more favorable than Abbott Laboratories.

Institutional & Insider Ownership

72.3% of Stryker shares are owned by institutional investors. Comparatively, 73.0% of Abbott Laboratories shares are owned by institutional investors. 6.7% of Stryker shares are owned by company insiders. Comparatively, 1.5% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Stryker and Abbott Laboratories' revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Stryker. Abbott Laboratories is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and Abbott Laboratories' net margins, return on equity and return on assets.

Dividends

Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 0.9%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Stryker pays out 33.9% of its earnings in the form of a dividend. Abbott Laboratories pays out 49.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 1 consecutive years and Abbott Laboratories has increased its dividend for 49 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Volatility and Risk

Stryker has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Summary

Abbott Laboratories beats Stryker on 9 of the 17 factors compared between the two stocks.

Abbott Laboratories (NYSE:ABT) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for Abbott Laboratories and Becton, Dickinson and, as provided by MarketBeat.com.

Abbott Laboratories presently has a consensus price target of $124.6667, indicating a potential upside of 3.05%. Becton, Dickinson and has a consensus price target of $276.75, indicating a potential upside of 8.21%. Given Becton, Dickinson and's higher possible upside, analysts plainly believe Becton, Dickinson and is more favorable than Abbott Laboratories.

Institutional & Insider Ownership

73.0% of Abbott Laboratories shares are held by institutional investors. Comparatively, 83.3% of Becton, Dickinson and shares are held by institutional investors. 1.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.8% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Abbott Laboratories and Becton, Dickinson and's top-line revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and Becton, Dickinson and's net margins, return on equity and return on assets.

Dividends

Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Becton, Dickinson and pays an annual dividend of $3.32 per share and has a dividend yield of 1.3%. Abbott Laboratories pays out 49.3% of its earnings in the form of a dividend. Becton, Dickinson and pays out 32.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Abbott Laboratories has raised its dividend for 49 consecutive years and Becton, Dickinson and has raised its dividend for 50 consecutive years.

Risk and Volatility

Abbott Laboratories has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Summary

Abbott Laboratories beats Becton, Dickinson and on 10 of the 17 factors compared between the two stocks.

Abbott Laboratories (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for Abbott Laboratories and Edwards Lifesciences, as provided by MarketBeat.com.

Abbott Laboratories presently has a consensus price target of $124.6667, indicating a potential upside of 3.05%. Edwards Lifesciences has a consensus price target of $117.9333, indicating a potential upside of 5.04%. Given Edwards Lifesciences' higher possible upside, analysts plainly believe Edwards Lifesciences is more favorable than Abbott Laboratories.

Institutional & Insider Ownership

73.0% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 80.3% of Edwards Lifesciences shares are owned by institutional investors. 1.5% of Abbott Laboratories shares are owned by company insiders. Comparatively, 1.4% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Abbott Laboratories and Edwards Lifesciences' revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Edwards Lifesciences. Abbott Laboratories is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and Edwards Lifesciences' net margins, return on equity and return on assets.

Volatility & Risk

Abbott Laboratories has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Summary

Edwards Lifesciences beats Abbott Laboratories on 8 of the 14 factors compared between the two stocks.

Abbott Laboratories (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Abbott Laboratories and Boston Scientific's revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Boston Scientific. Abbott Laboratories is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Abbott Laboratories and Boston Scientific, as provided by MarketBeat.com.

Abbott Laboratories presently has a consensus price target of $124.6667, indicating a potential upside of 3.05%. Boston Scientific has a consensus price target of $48.91, indicating a potential upside of 7.26%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Boston Scientific is more favorable than Abbott Laboratories.

Profitability

This table compares Abbott Laboratories and Boston Scientific's net margins, return on equity and return on assets.

Institutional & Insider Ownership

73.0% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 89.6% of Boston Scientific shares are owned by institutional investors. 1.5% of Abbott Laboratories shares are owned by company insiders. Comparatively, 0.7% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Abbott Laboratories has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.

Summary

Abbott Laboratories beats Boston Scientific on 8 of the 15 factors compared between the two stocks.